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Methods: This was done by collecting data of urinary pathogens from:
Urology, Internal Medicine and Cardiology wards. Antibiotic sensitivity
was determined according to NCClS standards. Consumption of antibio-
tics was estimated with using DDD index.
Results: Percentage ofisolated microbes from UTI depends on a specificity
of the ward. Gram-negative rods remaind the commonest pathogens,
mainly Escherichia coli, being 30-70% in some wards. Pseudomonas and
Alinetobacter were isolated only from Internal Medicine and Urology.
Periodically changes were observed in isolation of some resistant strains
from wards, e.g. increase ofPseudomonas, Enterococcus and Candida in Internal
Medicine, Serratia in Urology, decrease of Proteus in Cardiology. Resistant
strains were isolated more often during increasing consumption of anti-
biotics mainly quinolons, cephalosporins and amoxicillin/clavulanic acid
only in Internal Medicine and Urology.
Conclusions: Only current analysis ofmicrobiological data allows to create
the most appropriate antibiotic policy in hospital and can deals to decrease
bacterial resistance and costs of treatment.
IMoP229I An evaluation of antimicrobial resistance of gram-
negative isolates in intensive care units (lCU)
N. Saltoglu, Y. Tasova S. Incecik, 1. H. Diindar
(::ukurova Univerlity Hospital, Infectious Diseases Dept. Adana, Turkey
Objectives: To determine antimicrobial resistance patterns among gram
negative microorganisms isolated from ICU patients at C;:ukurova Uni-
vercity Hospital.
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IWeP224! A randomized comparison of levofloxadn versus a
third generation cephalosporin with or without a macrolide in
the treatment of not severe community-acquired pneumonia
E. Coma, P. Domingo, M. Gurgui, F. Sanchez, N. Rabella
Hospital de la Santa Creu i Sant Pau, Dept. Internal Medicine, Barcelona,
Spain
Background: The aim ofthis study was to compare the efficacy and safety of
levofloxacin versus ceftriaxone with or without a macrolide in the treatment
of community acquired pneumonia (CAP).
Patients and methods: From January 1999 to June 1999 we prospectively
studied 100 patients with CAP. CAP was defined as the presence of
symptoms of lower respiratory tract infection, along with a new infiltrate
on chest radiography and no emerging alternative diagnosis during follow-
up, in a patient not hospitalised for at least the previous 72 h. Patients were
excluded for severe immunosupresion (neutropenia < 500 celI/mm3), the
shock septic, the predisposition to aspiration, the pregnancy and woman's
we arc in the suckle period. Patients were assessed randomisedly to received
levofloxacin 500 mg daily iv or vo (group I) or ceftriaxone 2 g daily/
cefuroxime 1 g daily vo associated or no to macrolide (group II).
Results: Ofthe 100 patients randomised, 95 were analysed. 48 were assigned
to group I and 47 to group II. There were not statystically significant
differences in the patient baseline characteristics. We analysed the sputum in
39 patients (41 %), 14 (35%) were monomicrobians and 25 were not
evaluables. The most frequent pathogens were S. pneumoniae (7 patients
17%), Haemophilus influenzae (6 patients 15%) and Esceriehia Coil (1
patient 2%). Regular sampling ofserum for paired serology were analysed
in 64 patients (68%): Influenza A 12 patients (19%), Influenza B 6 patients
(9%), Clamydia pneumoniae 1 patient (l %), Legionella sp. 1 patient (I %).
Not statistically significant difference was reported between of the duration
of the fever and the mean hospital stay. During the study, patients were
monitored to detect the appearance of adverse events, only 4 patients (8%)
treated with levofloxacin presented diarrhoea.
Conclusions: levofloxacin is at least equally effective than ceftriaxone with
or without the addition ofa macrolide in the treatment ofnot severe CAP. It
is usually well tolerated and its main side effect has been mild diarrhea.
Methods: DuringJuly-December 1999 100 cultures from 81 patients with
various clinical manifestation of nosocomial infection were isolated. Identi-
fication and antibiotic susceptibility of isolates were tested by Sceptor sys
MIC/ID panels (Becton Dickinson). Susceptibility to ciprofloxacin, imipe-
nem, amicasin, gentamicin, ceftazidime, ceftriaxon, cefuroxim, piperacillin
were examined.
Results: Of 81 pts were 51 male and 30 female. The body sites yielding
specimens arc following: respiratory tract 14%, urinary tract 35%, blood
11 %, wounds 20%, others. 19% isolated gram (-) patogens were, 25% E.
coli, 21 % Klebsiella spp., 19% Acinetobacter spp., 16% Pseudomonas, 6%
Proteus spp, 4% Citrobacter. The most frequently isolated five pathogens'
antimicrobial agents resistance to 11 of them detected as follows:
Antimicrob. resist. Entero- Pseudo- Acineto-
(%) E. coli Klebsiella bacter monas bacter
lOlipcnem 14 9 14 25 16
Ceftriaxon 45 55 33 R6 84
Ceft3zidime 50 57 83
Cefuroxime 47 71 90 92
Amicacin 20 9 33 37 74
Gentamicin 21 44 50 43 6(,
Amp.-Sulb. 88 80 77 63
Ciprofloxacin 45 50 11 37 55
Ticar. -Clav. 80 73 37 33 60
Condusions: As a result the isolated gram (-) microorganism from ICU,
there is a high level antimicrobial resistance. The most sensitive antimicro-
bial agent was imipenem.
IWeP22S1 dinical study on the effect of total alkaloid
extracts of berberis plant on the dental plaque in children
N. Khalili1, A. Makarem2, R. Asodeh l , B. S. Fazly-Bazzaz1
'School ofPharmacy; 2School of Dentistry, Mashhad, Iran
Objective: Berberis plants owing many active alkaloids, the main ofwhich is
berberine that showed antimicrobial activities. Therefore, the possibility of
using alkaloids extracts as a medicine to reduce or eliminate the dental plaque
in children was investigated.
Methods: Microbiological: the antimicrobial activity (MIG) of the dried
alkaloids extracts against several bacterial and fungal species was determined,
using determined, using pour plate method with Muller-Hinton Agar
Medium.
Chemical: the alkaloids extracts were standardized according to their
berberine content using spectrofluorometric method. The effect of pH and
temperature on the oxidation of berberine was studied to determine the
max. stability region and the activation energy of the active substance,
respectively. A suitable dental gcl containing alkaloids extract of berberis
plant equivalent to 1% berberine at pH 5 was formulated. Clinical: berberis
gel was applied to 11-12 years children, their dental plaque index (PI) before
and after application were determined using disclosing agent which colors
only the plaque spots according to their severity. At the same time blank gel
(without alkaloids extract) and a commercial dentifrice were applied.
Results: MICs were between 0.2-7 mg dried extract per ml. The max.
stability was at pH 5 and the activation energy about 42.6 kcal/mole.
Clitlically, berberis alkaloids extract gel could significantly reduce the main
plaque index in children and has extremely significant difference from blank
and is slightly more active than commercial one.
Condusion: Using dental gel containing berberis alkaloids extract could
reduce or eliminate the dental plaque in children.
IWeP226I Management of H. pylori resistant strains:
Quadruple therapy after triple therapy failure
M. V. Zanetti. R. Vendramin, O. Pieramico1
Laboratory of Microbiology; I Divisiotl of Internal Medicine, General
Hospital"F. Tappeiner", Merallo, Italy
Triple therapy (TT) with a proton pump inhibitor (PPI) in combination
with two antibiotics cures H. pylori infection (HP) in about 90% ofcases. It
is debated how to treat patients with antibiotic resistance (R) and TT failure.
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Alms: to evaluate efficacy, compliance and safety of a PPI-quadruple
therapy in patients with antibiotic R and previous TT failure.
Patients and Methods: 27 patients (16 M. 11 F. age 32-65 years) with
persisting HP after TT with omeprazole 20 mg bid, clarithromycin 500 mg
bid and 1) metronidazole 500 mg bid (OMC; n = 13) or 2) amoxicillin 1 g
bid (OAC; n = 8) and infected with metronidazole R (n = 16) and/or
clarithromycin R strains (n = 10) were included. Nine patients were
resistant to both metronidazole and clarithromycin. At each endoscopy
performed before and 6-10 weeks after end of therapy, five biopsies were
taken from antrum and corpus for rapid urease test. histology and culture.
Antibiotic susceptibility was performed with disk-diffusion technique (DD)
and metronidazole and c1arithromycin R were defined according to the
most recent literature (S. Chaves.]. Clin. Microbiol., May 1999,37: 1628-
1631; Weissfeld et al. 1998). Patients were then treated with omeprazole 20
mg bid, bismuth subcitrate 120 mg qid. metronidazole 500 mg bid and
tetracycline 500 mg bid for 14 days.
Resul15: all patients except one have completed therapy. Mild side effects
were reported by 27% HP was cured in 24/26 patients (per-protocol 92%,
95% CI 81-HlO; ITT 89%, 95% CI76-11X)).
Conclusions: I) a 14-days course of PPI-based quadruple therapy has high
efficacy irrespective to antibiotic resistance and is well tolerated; 2) PPI-based
quadruple therapy should be considered after triple therapy failure in
patients with metronidazole and/or clarithromycin resistance.
IWeP221I The compartson of two anti-helicobacter pylori
regimens
M. Avijegan, S. M. K. Hosseini assl, M. Bassirat nia
University ofMedical Sciences of Shahr-e-Kord, ShallT-e-Kord, Irall
This study was catried out to compare two anti-helicobacter pylori regi-
mens. This study included patients who were referred to endoscopic section
ofKASHANI hospital mainly due to hematemesis, melena, intractable and
long time epigastric pain with peptic ulcer in their endoscopy. The exclusion
criteria were negative ureas test and helicobater pylori (H.P) in biopsy
sample with gimssa stain. They were between 14-80 years old. The male to
female ratio was 1.1 :2. Also 21/3% of them had familial history of peptic
ulcer (p.U). Based on the exclusion criteria 14 cases out of61 patients in the
first endoscopy have been excluded from the study. The patients have
randomly been devided into groups A and B.
The regimen of group A consisted of omeprazol 20 mg BIO +
amoxicillin 500 mg QIO + metronidazol 250 mg TDS/daily for two
weeks, and regimen of group B consisted of bismuth 120 mg BID +
tetracyclin 250 mg QIO + metronidazol250 mg TOS/daily for two weeks.
One month later than the end treatment, they have been invited for second
endoscopy and noted for positive H.P and ulcer healing.. 26 cases received
regimen A and 21 cases regimen B. 17 cases ofgroup A (11 cases absent) and
18 cases of group B (3 cases absent) have attended for the second endoscopy.
One patient of group A and 3 patients of group B were excluded based on
the exclusion criteria. H.P had been eradicated in 67/7% of group A and in
60% of group B. also healing rate was 75% in A and 66/6% in B. The
difference between two groups was not significant (P = 0/05). The small
insignificant higher H.P-eradication and healing rate might favores the use
of regimen A.
IWeP228j Sitafloxacin in the treatment of patients with
Infections caused by vancomycin-resistant enterococci (VRE) and
methicillin-resistant Staphylococcus aureus
N. Shetry, A. P. R. Wilson
Department ofClinical Microbiology, University Col/ege London Hospitals,
Lotldon, United Kingdom
Objectives: Sitaftoxacin is a new quinolone with activity against vancomy-
cin resistant enterococci (VRE) and methicillin-resistant Staphylococcus
aureus (MRSA). As clinical experience is limited. a preliminary open,
uncontrolled and non-blinded study was conducted in patients with serious
systemic infections caused by multi-resistant Gram positive pathogens.
MRSA patients had already failed treatment with glycopeptides.
Methods: Patients with serious systemic infections with MRSA or VRE
were recruited into a non-eompuative phase II trial using sitafloxacin 400
mg iv once a day for 7-14 days. Strict inclusion and exclusion criteria were
followed on recruitment. Cure was defined as resolution of all infection-
related signs and symptoms, an improved SOFA score and no further
antibiotic treatment.
Resul15: Of II patients with MRSA infection, four were cured. six failed
treatment and one was indeterminate. Of9 patients with VRE infection (one
patient had both pathogens), five were cured and four failed clinically
although six were bacteriological successes. Fifteen adverse events in 12
patients were thought to have some relationship to the study drug. Four
patients (one withdrawn) developed rash and one developed transient fits
and was withdrawn. Trough serum concentrations of sitafloxacin ranged
from 0.15-4.3 mg/L; peak concentrations from 3.4-29.9 mg/L.
Condusloll5: Sitaftoxacin waS found to be a useful drug in treating patients
in whom glycopeptides had already failed or were likely to be ineffective.
IWeP229I cefuroxime axetil (CAE) compared to cefpodoxime
proxetil (CPD) in the treatment of acute exacerbation of chronic
bronchitis (AEeB)
]. Gaillat', C. Baranes2• O. Amsellem2, A. Cohen2, N. Bougon·'. V.
Riebbels3, E. Chauveau3
ICentre hospilalier, Annecy; zParis; JGlaxo WeI/come, Marly-le-Roi, France
Objective: To demonstrate that the clinical efficacy of oral CAE 250 mg
twice daily is equivalent to that oforal CPO 200 mg twice daily in a lO-day
treatment of AECB.
Methods: This multicentre. randomised. open-label study was performed
in 50 centres. AECB was defined '15 sputum purulence and an increase in
severity of two other symptoms within sputum volume, cough or dyspnea.
Clinical efficacy, classified as success (cure + improvement) or failure, was
assessed at the end of treatment (days 10-12) and at follow-up (days 30-40).
All patients were assessed for safety analysis. Intent-To-Treat (ITT) and Per-
Protocol (PP) analyses.
Resul15: A total of 268 patients (130 CAE, 138 CPD) were randomised
between March and May 1999. At the end of treatment, clinical success rates
were equivalent with 95% ofsuccess in the CAE group and 92% in the CPD
group. At follow-up, equivalence was also demonstrated in the ITT analysis
with clinical success rates of 94% and 91 % for patients receiving CAE and
CPD respectively. A secondary efficacy criterion based on resolution of
sputum purulence only provided equivalent success rates in both treatment
groups as well (97% ofpatients treated by CAE and 96% ofpatients treated
by CPO). The most common adverse events were diarrhea (2%) in the CPO
group, and headache (2%) in the CAE group. Six% of CPD patients
reported gastrointestinal (GI) drug-related events compared to 1% of
CAE patients (p = 0.04). No unexpected side effect were observed.
Condusions: Cefuroxime axetil 250 mg twice daily demonstrate< efficacy
equivalent to cefpodoxime proxetil 200 mg twice daily in treatment of
AECB in adults. Both regimens were well tolerated. However GI events
were less frequent with CAE.
IWeP230 lin vitro and in vivo investigations of an Innovative
topical drug formulation for infection treatment and wound
healing: Povidone iodine Iiposome hydrogel
K. Reimer'. P. M. Vogt2• B. Broegmann',]. Hauser2, O. Roszbach2• A.
Kramer3• P. Rudolph3, B. Bossel • H. Schreier4 , W. Fleischer'
IM'mdipharma GmbH, Limburg; zUniversitatsklinikjiir Plastische Chirurgie,
Ruhr-Universtitiit Bochum; Jlnstitutjiir Hygiene, Universitiit Greifswald,
Germany; 'Sebastopol, CA, United States
ObjectIve: Evaluation ofa new topical formulation consisting ofa complex
of the antiinfective agent povidone iodine (PVP-I) with liposomes in a
hydrogel base allowing for both antiseptic and moist treatment ofwounds.
Methods: Pharmaceutical formulation of the complex of 3% PVP-I and
phosphatidylcholin in a hydrogel. In vitro, interaction of the complex with
relevant micro-organisms was analyzed by scanning electron microscopy.
Tissue toxicity was examined by explant test in a rat model (Kramer et al.
1998).
A randomised clinical study on efficacy and tolerability in wound healing
was carried out on 35 patients with meshgrafts in parallel groups (pVP-l
Iiposome hydrogel vs. Bactigras).
Results: A direct interaction of the PVP-I liposomes with mirco-organisms
(c. albicans and E. coli) by attachment to the cell surface was documented. A
significantly better cell and tissue tolerability of the PVP-I liposome
hydrogel compared to equivalent conventional PVP-I formulations was
shown.
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The results of the clinical study, especially measurements of neo-epithe-
Iialization per time and the area of transplant loss, demonstrate significant
differences in favour of the PVP-lliposome hydrogel.
Conclusion: The novel PVP-I liposome hydrogel combines microbicidal
and wound healing activities resulting in enhanced epithelialization.
IWeP232I Cefepirne vs imipenem for nosocomial pneumonia
in ICU patients
G. Zanetti!, F. Ballyl, D. Aymon!, T. Kinge2, D. Lew2, L. Strachunskl,
L. Krawczyk4, G. Greub', M. P. Glauser
The Cejepime Study Group; 'Lausanne; 2Geneva, Switzerland; JSmolensk.
Russian Federation; 4Sosnowiec. Polatld
Objectives: compare efficacy and safety of cefepime (CEP), 2 g tid, and
imipenem/cilastatin (IMP), 0.5 g qid as monothcrapy for nosocomial
pneumonia (NP) in ICU patients.
Method: Prospective, randomized, open-label, evaluator-blind srudy, con-
ducted in 13 centers from 6 european countries. Definition ofNP was based
on clinical and radiological criteria.
Results: Among 281 randomized patients, 270 (%%) were eligible for
modified intent-to-treat analysis. 66% of them had mechanical ventilation.
The mean APACHE II score was 16 at randomization. Microbiological
documentation was available in 180 patients (67%). The most frequent
causative organism was Pseudomotlas aeruginosa (70 patients). An ESBL-
producing organism was found in 28 patients. Success rate (cure or
improvement) was similar with CEP (78/132, 59%) and IMP (78/138,
57%). Among microbiologically documented NP, eradication rates were
52% with CEP and 44% with IMP (95%CI for risk difference: -7%-23%).
Clinical failure was attributed to resistance of the causative organism in 5.3%
of the patients in CEP and 5.8% in IMP. Emergence of resistance to the
allocated regimen occurred in 6/147 (4.1 %) causative organisms in CEP and
9/131 (6.9%) in IMP (p = 0.4). AII-cause mortality up to 30 days after
protocol completion was 31 % in the CEP group and 27% in the IMP group.
NP contributed to death in 11/132 patients in CEP and 8/138 in IMP (p =
0.48). The overall incidence ofadverse events was similar in the 2 treatment
groups (57% in CEP, 48% in IMP).
Condusion: CEP was clinically and microbiologically as effective as IMP
for monotherapy ofNP in ICU patients.
[WeP233J Daptomycin treatment of serious gram-positive
infections
F. P. Tally, C. Berman, F. B. Oleson, M. F. DeBruin
Cubist Pharmaceuticals, Cambridge, MA. United States
Daptomycin is a novel lipopeptide antibiotic that is bactericidal in vitro
against drug-susceptible and drug-resistant Gram-positive bacteria, includ-
ing the enterococci. A Phase 2 study ofdaptomycin at a dose of6 mg/kg per
day, (given as 3 mg/kg/qI2 hrs.), for the treatment of bacteremia and
endocarditis showed favorable clinical and bacteriological outcomes. In
bacteremia patients 17 ofl9 had favorable results, including 9 ofl0 patients
with Staphylococcus aureus infections. In patients with endocarditis, II ofl7
of daptomycin-treated patients (65%) had favorable clinical and bacterial
results, as compared to 7 of 10 patients (70%) on conventional therapy.
Recent in vivo animal studies have shown that once-a-day therapy is
optimal for antibacterial efficacy and increases safety. Two on-going
open-label trials are in progress in bacteremia patients to evaluate the
safety of once-daily daptomycin dosing. The bacteremia trial (BAC)
randomizes adult patients with > 2 positive blood cultures and clinical
signs ofsystemic infection. Daptomycin regimens arc 6 or 4 mg/kg q24h, or
6 mg/kg as a loading dose followed by 3 mg/kg ql2h. Patients randomized
to standard therapy receive either intravenous vancomycin 1 gm ql2h or
oxacillin/nafcillin 4-12 gm/day in divided doses, based on the clinical
judgement of the investigator. The second trial (RRC) enrolls patients
bacteremic with a Gram-positive organism resistant or refractory to stan-
dard therapy, or for whom standard therapy is contraindicated. Enrollment
in the BAC and RRC trials is progressing. To date, all dosing regimens of
daptomycin have been well tolerated. Updated safety and clinical outcome
results from patients bacteremic with drug-susceptibIe and drug-resistant
organisms (e.g., VRE) will be presented.
[WeP234I Comparative clinical study of ZIRAON (evemlmicin)
and ceftrlaxone for acute bacterial pneumonia caused by
penicillin-resistant Streptoeoeeus pneumoniae
G. M. Mukwaya, A. Barry,]. M. Hill, T. Soler,]. Tsitsi
Scheritlg-Plough Research Institute, Kenilworth, Nj, United States
Objectives: Two multicenter, randomized, dose-ranging, evaluator-blind,
studies compared the efficacy and safety of once daily ZIRACIN (ever-
Dimicin) (ZIR), (1,3 or 6 mg/kg/day] a potent everninomicin antibiotic,
with that ofceftriaxone (CEF) [2 g/day) in the treatment ofpneumonia due
to penicillin-resistant Streptococcus pneumoniae (PRSP).
Methods: Antimicrobial susceptibility was determined using micro-broth
dilution and E-test methods on baseline blood and spurum cultures isolated.
S. pneumoniae was penicillin (PCN) susceptible when the MIC was ~0.06
mcg/mL; PCN resistance was defmed to be intermediate at an MIC ofO.l-
1.0 mcg/mL and high-level at ~2 mcg/mL. Clinical and microbiological
responses were determined at day 4 and one ofdays 13 -15. Clinical response
was positive if patients were cured (resolution ofall signs and symptoms) or
improved. A positive microbiological response was defmed as bacterial
eradication or presumed eradication.
Results: 6/88 culrures isolated from pts with pneumonia were high-level
PCN resistant, 5/88 were intermediate-level resistant. The mean MIC for
ZIR was 0.026 mcg/mL for the high- and 0.033 mcg/mL for the inter-
mediate-level PRSP. For CEF, the mean MIC was 2.8 mcg/mL and 0.878
mcg/mi, respectively. 4/6 high-level and 4/5 intermediate-level PRSP were
from pts treated with ZIR, the rest received CEF. All 11 PRSP pts showed
positive clinical and microbiological responses at both visits. Only 3/11 pts.
(2 CEF, 1 ZIR) reported adverse events.
Conduslons: ZIR was as effective as CEF for the treatment PRSP acute
pneumonia as evidenced by the positive clinical and microbiological
responses to either srudy drug. Both study drugs were well tolerated.
IWeP235 \ Comparative study of ZIRACIN (evemimicin) vs
ceftriaxone in bacteriologically proven acute pneumonia caused
by Streptoeoeeus Pneumoniae
G. M. Mukwaya,]. Tsitsi,]. Hill, B. Luke, G. Martinez
Scheritlg-Plough Research Institute, Kenilworth Nj, United States
Objectives: ZIRACIN (evernimicin) (ZIR), an everninomicin antibiotic,
was compared to ceftriaxone (CEF) in 2 randomized, evaluator-blind, dose-
ranging studies for the tre.:ltment ofgs r::ttientf;. w-ith b:tteriologiaHy proven
Streptococcus pneumoniae pneumonia.
Methods: At baseline, S. pneumoniae was isolated from spurum, pleural
Buid or blood cultures in all patients. Patients were randomized to ZIR (1. 3,
or 6 mg/kg/d) or CEF (2 mg/kg/d) once daily IV for 3 days, followed by
amoxicillin (1 g tid) for 7 days. Clinical and microbiological responses were
evaluated at day 4 (end of IV therapy) and one of days 13-15 (end of
antibiotic therapy). Positive clinical responses were defined as cure or
improvement. Positive microbiological responses were defined as eradica-
tion or presumed eradication.
Results: At both evaluations, positive clinical responses were achieved in
75% of 16 patients that received 1 mg/kg/day ZIR and 97% of29 patients
that received 3 mg/kg/day. All 12 patients treated with 6 mg/kg/day ZIR
and all 31 patients who received 2 g/day CEF had positive clinical responses.
The microbiological responses paralleled the clinical responses. Thirteen
percent (11/88) of the bacterial isolates were high- or intermediate-level
penicillin resistant.
Conduslons: ZIR, at doses 3 or 6 mg/kg/day, was as effective as CEF at 2 g/
day, in the treatment of patients with bacteriologically proven pneumonia
caused by S. pneumoniae
IWeP236! Comparative eed of moxifloxadn and co-
amoxidav in the treatment of AEca
T. Schaberg
The AECB Study Group; Chest Clinic Unterstedt, Rotenburg, Germany
Objectives: To compare the efficacy and safety of5 days' oral moxiBoxacin
(MXF; 400 mg, od) with 7 days' oral co-amoxiclav (CLA/AMX; 625 mg
tid).
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Methods: This was a multinational. randomized. non-blinded study con-
ducted in 575 patients with AECB characterized by purulent sputum and
either/or increased sputum volume and increased dyspnoea.
Results: Seven days post-therapy. resolution was achieved in %.2% (251/
261) ofefficacy evaluable patient~ in the MXF group and 91.6% (230/251) of
patients in the CLA/AMX group (95% confidence interval: 0.4%. 8.7%).
indicating superiority for MXF. At follow-up (21-28 days post-treatment).
the continued resolution rates were 93% and %% for MXF and CLA/
AMX. respectively. A total of 140 patients were microbiologically evalu-
able. Eradication rates for the most common pathogens were: H. influenzaf
85.7% (24/28) for MXF and 87.5% (28/32) for CLA/AMX; S. pnfumoniaf
93.3% (14/15) for MXF and 100% (10/10) for CLA/AMX; M. cata"halis
92.9% (13/14) for MXF and 100% (12/12) for CLA/AMX.
Conclusions: A 400 mg dose of moxiftoxacin. given once daily for 5 days
was equivalent in efficacy to 625 mg ofco-amoxiclav dosed three times daily
for 7 days to adult patients with AECB.
IWeP237I Comparison of Iinezolid versus ceftriaxonel
cefpodoxime in the treatment of hospitalized patients with
community-acquired pneumonia
S. K. Cammarata'. G. S. San Pedr02.). A. Timm'. K. A. Hempsall l • w.
M. Todd l • T. H. Oliphant l • B. Hafkin l
Ilnffctious Disfasfs Clillical Research. Pharmacia & Upjohn, Inc, Kalamazoo,
MI; zLou;s;ana Stale UIl;versily Medical Cmler, Shreveport, LA. United
Slales
Background: Linezolid (LZD). an oxazolidinone. is completing phase III
trials for use in community-acquired pneumonia (CAP). This study eval-
uated the efficacy oflinezolid in trearment ofhospitalized patients with CAP.
Methods: This randomized open label trial of hospitalized patients with
CAP compared either IV LZD 600 mg BID or IV ceftriaxone (CTX) 1 gm
BID prior to switch to PO LZD 600 mg BID or PO cefpodoxime (CPD)
200 mg BID. Followup occurred at 15-21 days after end of therapy.
Results: 381 patients received LZD; 366 patients received CTX/CPD.
Average length of therapy was 11 days. LZD clinically cured 90.8% (247/
272) versus 88.6% (225/254) cured with CTX/CPD (p = 0.4. clinically
evaluable patients excluding missing and indeterminate). S. pneumoniae was
the most frequently isolated pathogen. The microbiologic outcome for
microbiologically evaluable patients again showed LZD to be equivalent to
CTX/CPD with microbiologic success in 89.9% (80/89) LZD patients vs.
87.1 % (81/93) CTX/CPD patients. Adverse events were generally mild to
moderate in nature with diarrhea and nausea being the most common drug-
related CVCtlu.
Conclusion: Linezolid is an effective. well tolerated agent in treatment of
hospitalized patients with CAP.
IWeP23S1 Unezolid Is eective against penicillin-resistant
Streptococcus pneumoniae (PRSP) in hospitalized patients with
community-acquired pneumonia
S. K. Cammarata'. R. Nahass2• W. T. Todd'. T. H. Oliphant'. B.
Hafkin'
IPharmacia & Upjohn, Kalamazoo, MI; zSomerset Medical Cfnler,
Somerville, Nj, Uniled Slatfs
Background: Linezolid (LZD). an oxazolidinone. has activity against gram
positive organisms. including organisms resistant to penicillin and other
antibiotics. This study evaluated the efficacy of LZD in the treatment of
hospitalized patients with community-acquired pneumonia (CAP). includ-
ing those with PRSP.
Methods: This open-label. randomized trial in the treatment of patients
hospitalized with CAP evaluated IV LZD 600 mg BID switched to PO LZD
600 mg BID versus IV ceftriaxone (CTX) 1 gm BID prior to switch to PO
cefpodoxime (CPD) 200 mg BID. Follow-up occurred at 15-21 days after
the end of treatment.
Results: For the 759 patients randomized. Streptococcus pneumoniae was
the most common pathogen. seen in 141 of 185 microbiologically evaluable
(ME) patients. For all S. pneumoniae isolates. LZD provided microbiologic
success in 88.7% (63/71) ME patients. versus success in 89.9% (62/69) of
CTX/CPD treated ME patients. Of the 141 S. pneumoniae isolates. for
LZD. 12.7% (9/71) of isolates had intermediate susceptibility to penicillin
(PISP) and 5.6% (4/71) were resistant to penicillin (PRSP). similar to the
CTX/CPlJ arm where 12.9% (9/70) were PISP and 1.4% (1/70) were
PRSP. The microbiologic success rates for patients with baseline PISP and
PRSP were 77.8% (7/9) and 100% (4/4). respectively. for LZD patients and
100% (9/9) and 100% (1/1) for CTX/CPD patients, excluding patients with
indeterminate or missing outcomes.
Conduslon: Linezolid is an effective treatment for S. pneumoniae pneumo-
nia. including penicillin-nonsusceptible strains.
[weP239] Unezolld eradicates common pathogens in
community-acquired pneumonia
S. K. Cammarata1. H. Standiford2• W. M. Toddl • T. H. Oliphant'. B.
Hafkin l
IPharmacia & UP.iOhll, Kalamazoo, MI; 2Ba/timorr VA Medical Cmter.
Ba/timore, MD, Ullited Stales
Background: Linezolid. the first in a new class of antibacterials. the oxazo-
Iidinones. has been tested in clinical trials for the treatment of community-
acquired pneumonia (CAP) with both IV and oral formulations. This
summarizes the eradication ofcommon bacterial pathogens in three clinical
trials.
Methods: One open label. non-eomparator controlled study compared 2
dose strengths oflinezolid (high dose 1125 mg-1250 mg/day.low dose 750
mg/day). while one randomized comparator controlled study examined the
efficacy oflinezolid 600 mg IV/po BID against ceftriaxone 1 gm IV BID/
cefpodoxine 200 mg po BID in hospitalized patients with CAP and a second
randomized comparator controlled trial evaluated Iinezolid 600 mg BID po
versus cefpodoxime 200 mg BID po in outpatients with CAP. Patients
received trearment for 7-14 days. Follow-up occurred at 15-28 days after
end of therapy.
Results: Of the 178 patients enrolled in the dose-eomparison trial. 73
patients were clinically evaluable with pathogens identified at baseline. Of
the 1307 patient enrolled in the comparator controlled trials. 282 patients
were clinically evaluable with pathogens identified at baseline. The micro-
organism eradication rates are outlined in the following table:
Linezolid Cephalosporin
Pathogen n/N* % n/N* %
H influenzae 16/18 88.9 23/26 88.5
S aureus 36/40 90.0 24/29 82.8
S pneumoniac 138/150 92.0 81/90 90.0
•n = number ofpathogens eradicated. N = number ofpathogens isolated atb~
line
Conclusion: Linezolid effectively eradicates the common bacterial patho-
gens seen in CAP.
IWeP240I Unezolid in the treatment of outpatients with
community-acquired pneumonia: European results
M. Molinari l • G. Garrera', M. H.]. Pimm2• W. DeCian1• T. Aronkyt03•
H. Giamarellou4
'Infeclious Diseases, Pharmacia and Upjohn, Milan, Italy; 2The Cfdars,
Weston S"per Mare, Uniled Kingdom; 3jorvi Hospital, Espoo, Finland;
4Sismanogliou Hospital, Athens. Greece
Background: Linezolid (LZD). the first in a new class of antibacterials. the
oxazolidinones. is effective against gram positive organisms with both IV
and oral formulations. In this trial LZD was evaluated in treatment of
outpatients with community-acquired pneumonia (CAP).
Methods: This investigator blinded. randomized study compared the
efficacy ofLZD 600 mg orally every 12 hours against cefpodoxime (CPD)
200 mg orally every 12 hours. Patients received treatment for 10-14 days.
Follow-up occurred at 15-21 days after end of therapy.
Results: In this global trial 540 patients were treated. 192 clinically evaluable
patients were from Europe. In these European patients. LZD clinically cured
90.2% (83/92) versus 90.4% (85/94) of the CPD treated patients (excluding
indeterminate or missing outcomes). LZD also provided microbiologic
success in 19 of 22 of patients with b2.~linC' pathogens venu.~ KUCCCSI. in 19
of21 CPD treated patients with pathogens. Adverse events were generally
mild to moderate in nature. with diarrhea. nausea. and headache being the
most common drug-related events.
Conclusion: Linezolid is an effective. well-tolerated agent in treatment of
outpatient CAP.
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IWeP241I Unezolid in the treatment of patients with
nosocomial pneumonia: European results
M. Molinari!, G. Garrera l , Z. Rort2, V. Kolek3, W. DeCian l
I Infectious Diseases, Pharmada and Upjohn, Milan, Italy; 2Hospital of
Matrahaza, Matrahaza, Hungary; JUniversity Hospital Olomouc, Czech
Republic
Background: Linezolid, the first in a new class of antibacterials, the oxazo-
Iidinones, has activity against gram positive organisms, both susceptible and
resistant. This trial evaluated linezolid, in combination with aztreonam, for
the treatment of nosocomial pneumonia (NP).
Methods: This double blinded, randomized study in patients with NP
compared the efficacy of linezolid (LZD) 600 mg IV BID against vanco-
mycin (vanco) 1 gm IV BID. All patients received coverage for gram
negative organisms with aztreonam 1-2 gm IV every 8 hours. Patients
received treatment for 7-21 days. Follow-up occurred at 12-28 days after
end oftberapy.
Results: In this global trial 396 patients were treated. 119 clinically evaluable
(CE) patients were from Europe. In these European patients, LZD clinically
cured 74.6% (44/59) versus 69.0% (40/58) of the vanco treated patients
(excluding missing and indeterminate outcomes). This was comparable to
outcomes seen in the global population. For those patients with a baseline
pathogen, LZD provided microbiologic success in 90.5% (19/21) ofpatients
versus success in 72.0% (18/25) ofthe vanco treated patients. Adverse events
were generally mild to moderate in nature, with diarrhea being the most
common drug-related event.
Conclusion: Linezolid with concomitant gram negative coverage is an
effective, well-tolerated agent in treatment of NP.
P:8/2 - Clinical trials of antimicrobial agents - II
IWeP242I Eect of step-down therapy of ceftriaxone plus
loracarbef versus parenteral therapy of ceftriaxone on the
intestinal microflora in patients with community-acquired
pneumonia
F. VogelI , G. Boden2, I. Nilsson-Ehle3, I. Odenholt4, C. E. Nords
IKrankenhaus Hojheim; 2Krankenhaus Bad Homburg, Germany; JUniv . Hosp.
Lund; 4Univ. Hosp. Uppsala; sKarolinska Inst., Stockholm, Sweden
Objectives: To compare tbe effect of two antibiotic regimens on the
intestinal microflora in patients with community-acquired pneumonia.
Methods: Twenty-five newly hospitalized patients with community-
acquired pneumonia participated in the investigation. Thirteen patients
received step-doWD therapy: initial treatment with ceftriaxone 1 g intrave-
nously q 24 h for 2 days followed by oralloracarbef 400 mg q 12 b for
additional 8 days. Twelve patients were given only parenteral therapy:
ceftriaxone 1 g intravenously q 24 h for 10 days. Stool samples were obtained
(1) before treatment, (2) on day 3 of treatment when patients were allocated
to the two alternative treatment regimens, (3) at the post-therapy visit, and
(4) at the late post-therapy visit. The stool samples were microbiologically
analyzed.
Results: In the patients receiving ceftriaxone, there was a significant
suppression of enterobacteria, bifidobacreria and clostridia, while there
was a pronounced overgrowth of enterococci and candida at the same
time. The microflora had returned to normal levels at the late post-therapy
visit. The patients who were treated with the step-down therapy ceftriaxone
plus loracarbef had a reduction of Escherichia coli, bifidobacteria and
clostridia and a minor increase in the numbers of enterococci and candida.
The microflora was normalized at the last visit.
Conclusions: The step-down therapy with ceftriaxone plus loracarbef did
not cause significant ecological alterations in the intestinal microflora
compared to parenteral ceftriaxone therapy in patients with community-
acquired pneumonia.
IWeP243I cefaclor In the chemoprophylaxis of recurrent
acute otitis media in HIV-infected children
G. V. Zuccotti, E. D'Auria, M. Torcolerti, L. Tegaldo, E. Riva
Department ofPaediatrics, San Paolo Hospital, Milan, Italy
Objective: To evaluate the efficacy ofCefaclor in the chemoprophylaxis of
recurrent acute otitis media (ADM) in HIV-infecred children
Subjects: Seventeen HIV infected children (9 males, 8 females) aged 2-12
years (mean 6, SD 2.6, median 7) suffering from recurrent AOM during Oct
1997-Mar 1998 (period 1) were enrolled. The patients were given cefaclor
(20 mg/Kg) once-daily for six months (Apr-Oct 1998) (period 2); a clinical
observation was carried out in the next six months (Nov 98-Mar 99) (period
3). Natural killer activity, phagocytosis and myeloperoxidase were deter-
mined just before and at the end of the prophilaxys. For each period the
average of two CD4 count was considered for the analysis. The number of
infections occurred in the different periods was compared.
Results: The treatment was associated with a reduction of the number of
infections in 100% of cases as compared with period 1 (p < 0.0001). No
significant differences were observed between periods 2 and 3 (p = 0.62).
Antiretroviral therapy was not related to the number ofinfections in any
period: period 1 (p = 0.63), period 2 (p = 0.51) and period 3 (p = 0.55).
Moreover, no differences were observed for CD4 count among the
different periods.
A mean increase of57% of myeloperoxidase activity was also observed.
Cefaclor was well-tolerated by all the patients.
COnclusions: We hypothesize that Cefaclor may be useful in the prophy-
lactic treatment of recurrent AOM in HIV-infected children.
IWeP244I Comparison of mechanical bowel preparation with
oral sodium phosphate and antibiotic preperation in colorectal
surgery
O. Biiyiikgebiz, A. <;ubuk~, S. Giindes l , O. Ozbay
Departments ofGeneral Surgery; I Microbiology, School ofMedicine, Kocaeli
University, Kocaeli, Turkey
Oral sodium phosphate (NaP) bas become an attractive alternative to other
agents for colonic cleansing. This study was performed to evaluate the
effectiveness ofmechanical bowel preparation with NaP on wound infection
in comparison with addition of preoperative ornidazol treatment. Fiftyfive
patients with co!orectal malignancies were randomized and all underwent
elective colorectal resection. Twentynine patients were men (52%) and 26
were women with an average age of59.6±2.6 (range 30-83). Dukes' stage
was similar and the surgical procedures equally distributed in the two
groups. Female/Male ratio was 1/1.4. Group I was consisted of32 patients
who were requested to take 45 ml NaP three times in a day and oral
ornidazol 1 g b.i.d in the following day and given intravenously (i.v.)
ceftriaxon 1 g plus omidazolSOO mg preoperatively. In group n, the patients
received 90 mL of NaP twice in the day before surgery and same i.v.
profylaxis as group I. The antibiotic treatments forwarded postoperatively
in the same manner. There were two wound infections for each group which
one was located in perineum for group I. No significant difference was noted
in the incidence ofpostoperative wound infection between the two groups.
Therefore, perioperative addition ofornidazol to a good mechanical bowel
preparation was of no benefit in reducing wound infections following
surgical procedures of colorectal malignancies.
IWeP24S1 Fluoroquinolones in severe Infections In children
Daniela Leca, V. Luca, Cata!inaLuca,
Egidia Miftode
Department of Infectious Diseases, University ofMedicine and Pharmacy, Ia#,
Romania
Objectives: To demonstrate the efficiency and optimal tolerance of fluor-
oquinoloncs in the treatment ofsevere infections, sistemic and located, with
gram negative baciIli and methiciJline-sensitive Staphylococcus in children.
Method: During a 3-year period, 270 children, 115 girls and 155 boys, aged
between 19 days and 16 years, with purulent meningitis (13 cases), sepsis (40
cases) and nosocomial salmonellosis (217 cases) were studied. Sensitivity to
fluoroquinolones was found to be 90% for Staphylococcus, 99.7% for
Salmonella and 100% for Escherichia coli, Klebsiella, Proteus mirabilis. Cipro-
floxacine (210 cases), Pefloxacine (57 cases) and Ofloxacine (3 cases) were
commonly used after the failure of the first-intention antibiotic therapy
(64.4%). Fluoroquinolones were administrated in association with synergic
antibiotics in 45.5% cases in severe forms and in immunocompromised
patients (64.8%). The average time oftreatment was 17.4 days in meningitis,
21.6 days in sepsis and 6.6 days in salmonellosis. The changement of therapy
was necessary in 9 cases.
Results: We noted a great clinical and bacteriological efficiency: 90% cure in
sepsis and salmonellosis and 80% in purulent meningitis. Only 1.48%
